We Should Revascularize Patients with Stable Coronary Syndromes and Ischemia Assessed by iFR

Chronic stable angina has shown a good response to medical treatment, and the Ischemia study has recently demonstrated the safety of such treatment in stable chronic angina with moderate to severe ischemia. However, this study excluded left main coronary artery (LMCA) lesions.

Debemos revascularizar los pacientes con síndromes coronarios estables e isquemia evaluada mediante iFR 

The FAME Study has shown the safety and efficacy of fractional flow reserve (FFR), as well as a reduction in the need for stent. However, in stable syndromes with ischemia assessed based on left main coronary artery physiology, it has not been analyzed whether current medical treatment is safe.

Researchers conducted a review of the DEFINE LM registry, which included 225 patients with stable chronic angina and significant lesions for ischemia, determined by instantaneous wave-free ratio (iFR) ≤0.89. Of these, 74 patients were deferred for medical treatment, while 151 patients underwent revascularization.

The Primary Endpoint (PEP) was defined as major adverse cardiovascular events (MACE), which includes mortality from any cause, non-fatal acute myocardial infarction, and revascularization of the LMCA lesion due to ischemia.

Since the populations were different, researchers conducted a propensity score match analysis, which resulted in 74 patients in each group.

The mean age of the participants was 71 years; 52% of patients were men and 80% had hypertension. Additionally, 42% had diabetes, 24% had chronic renal insufficiency, and 30% had experienced a previous myocardial infarction.

Read also: VASC-OBSERVANT II Substudy: Impact of Vascular Complications after TAVR.

The most common lesion in the left main coronary artery was distal (80%), followed by ostium lesions, while the lesion in the body of the LMCA was less frequent. There were no differences in the number of diseased vessels or in the presence of chronic total occlusion (CTO).

The SYNTAX Score was 22.

In the group of patients who underwent revascularization, percutaneous coronaryintervention (PCI) was performed in 44 cases, and myocardial revascularization surgery (MRS) was performed in 30 cases.

Read also: Calcified Nodules and the Importance of OCT Categorization prior PCI.

Follow-up was conducted over 34 months (22-40). Regarding the PEP, there was a benefit in favor of revascularization was, with an incidence of 14.9% versus 28.4% (hazard ratio 0.42 [95% confidence interval (CI), 0.20-0.89]; p=0.023). Furthermore, there was a reduction in cardiac mortality and LMCA-related myocardial infarction (0% vs. 8.1%; p=0.004), as well as in the need for revascularization of LMCA lesions (5.4% vs. 17.6%; hazard ratio, 0.20 [95% CI, 0.056-0.70]; p=0.012).

The predictor of MACE reduction was LMCA revascularization.

Conclusion

In summary, patients who underwent revascularization for stable coronary disease and significant lesions identified by iFR physiology had a more favorable long-term outcome compared to those whose revascularization was deferred.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Deferred Versus Performed Revascularization for Left Main Coronary Disease With Hemodynamic Significance.

Reference: Warisaw, et al. Circ Cardiovasc Interv. 2023;16:e012700. DOI: 10.1161/CIRCINTERVENTIONS.122.012700.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...